EODData

MEMBERSHIP REGISTER LOG IN

OTCBB, SRNE: Sorrento Therapeutics Inc

13 Nov 2025
LAST:

0.0075

CHANGE:
 0.00		OPEN:
0.0090		HIGH:
0.0100		ASK:
0.0000		VOLUME:
272.6K
CHG(%):
16.67		PREV:
0.0090		LOW:
0.0075		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
13 Nov 250.00900.01000.00750.0075272.6K
12 Nov 250.00750.00900.00550.0090569.7K
11 Nov 250.00550.00750.00300.0075773.5K
10 Nov 250.00800.01000.00750.00752.6M
07 Nov 250.00900.01430.00900.0090630.1K
06 Nov 250.00900.00900.00900.009076.1K
05 Nov 250.00800.01500.00800.0090270.1K
04 Nov 250.00800.01000.00800.0090693.7K
03 Nov 250.00720.00850.00720.0085128.7K
31 Oct 250.00910.01600.00710.0078765.4K

COMPANY PROFILE

Name:Sorrento Therapeutics Inc
About:Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as C
Sector:Healthcare
Industry:Biotechnology
Address:4955 Directors Place, San Diego, CA, United States, 92121
Website:https://www.sorrentotherapeutics.com
CUSIP:74838K306
CIK:0000850261
ISIN:US83587F2020
FIGI:BBG000BDLWR5
LEI:549300RH23PRR3M13410

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:0.018.0%
MA10:0.0112.0%
MA20:0.011.3%
MA50:0.0133.9%
MA100:0.0082.9%
MA200:0.00177.8%
STO14:15.00 
RSI14:59.04
WPR14:-50.00
MTM14:0.00
ROC14:0.25 
ATR:0.00 
Week High:0.0190.7%
Week Low:0.00150.0%
Month High:0.02113.3%
Month Low:0.00177.8%
Year High:0.101,213.3%
Year Low:0.007,400.0%
Volatility:43.32 

RECENT SPLITS

Date Ratio
01 Aug 20131-25